Haven't used Genteract yet?
Ask Trustburn

Questions about Genteract

Based on 9 reviews, listing data and website checks · updated 4 days ago

What is Genteract?

Genteract is a biotechnology company based in San Francisco, California, that develops a patented genetic discovery methodology to identify gene-environment interactions (GxEs). Their core technology combines this methodology with a genomic+metabolic AI foundation model trained on thousands of patients across multiple large-scale clinical studies. The company aims to enable functional interpretation of the human genome at a scale previously impossible to achieve.

How does Genteract's analysis differ from conventional methods?

The company's patented genetic discovery methodology detects genetically-defined sub-groups within a population who respond differently to a drug or environmental factor, and discovers all the SNPs significant in that difference. This approach contrasts with conventional analysis techniques that may find no significant change in a population's phenotype with increasing exposure to a drug or other environmental factor.

What types of data can Genteract analyze?

Genteract's analysis can work with any dataset containing genomic data, phenotypic data, and environmental data to discover new associations. They can also process gene expression, methylation, proteomic, and microbiome data alongside clinical trial or EMR data paired with genomic information.

What specific applications does Genteract offer for drug response prediction?

The company offers Drug Response Prediction to help payers save costs and improve care quality by predicting which drugs work best with the fewest side effects for each patient. They also provide Clinical Trial Optimization and Drug Repositioning to identify genetically-defined patient subgroups who respond differently to a drug, including new indications for existing drugs.

How can Genteract's technology help with FDA-rejected drugs and disease risk?

Genteract can help rescue drugs rejected by the FDA in phase III due to lack of broad efficacy by identifying patients who are strong responders through their test. They also assist in determining a patient's risk of diseases and finding pharmaceutical or nutritional interventions to mitigate that risk.

What is Genteract's vision for the future of medicine?

The company's vision is a future where precision medicine is the norm as a basic standard of care. Their insights learned from each clinical dataset are portable, meaning they improve foundation model performance for every subsequent predictive task because each dataset increases the model's understanding of human biology.

Who are the key people behind Genteract?

The core team includes Brody Holohan, PhD, as Co-Founder, CEO, and CSO, who developed the novel analysis methodologies and published seven peer-reviewed papers. Other advisors include Dr. Tim deMeyer from the University of Ghent and Dr. Jerry W. Shay from UT Southwestern, among others.

Where is Genteract located and how can I contact them?

The company is located at 139 Townsend Street in San Francisco, California. Their website is genteract.com, and they can be reached via email at [email protected] for data analysis inquiries.

What is the current rating and review history for Genteract?

According to Trustburn, Genteract has a rating of 4 out of 5 from 9 reviews. The most recent reviews are from November 2023, and the feedback is relatively recent.

What do reviewers say about Genteract's website and customer service?

Reviewers consistently praise Genteract's website for being efficient, intuitive, and easy to navigate. They also highlight the customer service team as outstanding, friendly, and always ready to assist with prompt responses.

How does Genteract's methodology improve upon current genetic discovery methods?

The company states that their methodology finds a much greater fraction of the SNPs in each GxE compared to current methodologies like genome-wide associations (GWAS), which miss many SNPs and cannot predict response for most GxEs.

What services does Genteract offer for clinical trials and data analysis?

Genteract can help identify new indications for existing drugs through their clinical trial optimization services. They also offer a no-obligation analysis of your data to create highly accurate GxE predictions with cross-validation.

What is the background of Genteract's lead data scientist?

The company's lead data scientist, Linda Banks, MS, has a background in quantitative biomedical science from Dartmouth and applied data science methods to establish biologically correct predictions of anti-drug antibodies.

Who are some of the advisors supporting Genteract?

Genteract's advisors include Dr. Bezia Lemma, a researcher at Princeton University, and Matthew Likens, former CEO of Ulthera, providing expertise in computational biology, genomics, and aging research.

Is Genteract on social media?

Genteract has official profiles on Linkedin.

Based on reviews, listing data and the company's website. Verify anything important with the company directly.

Questions & Answers

No questions yet — be the first to ask.

News & Press

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying widget on your website — its a simple way to convert your visitors into customers.

Embed code

<script src="https://trustburn.com/widgets/index.js"></script>
<div class="trustburn-widget" data-trustburn-protocol="https:" data-trustburn-domain="trustburn.com" data-trustburn-widget="score" data-company-path="genteract" data-lang="en"></div>
More widgets

About Genteract

Address
139 townsend street
Categories
Biotechnology